Success Metrics

Active Trials
2(100%)

Phase Distribution

Ph early_phase_1
2
100%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Early Phase 1First-in-human
2(100.0%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
2
Success Rate
N/A
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 12 (100.0%)

Trials by Status

recruiting2100%

Recent Activity

2 active trials
Showing 2 of 2
recruitingearly_phase_1

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

NCT06366451
recruitingearly_phase_1

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

NCT04541108

Clinical Trials (2)

Showing 2 of 2 trials
NCT06366451Early Phase 1

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Recruiting
NCT04541108Early Phase 1

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Recruiting

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2